RT Generic
T1 The Current Role of the Heavy/Light Chain Assay in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma: An Evidence-Based Approach
A1 Rios-Tamayo, Rafael
A1 Puig, Noemi
A1 Algarin, Macarena
A1 Garcia de Veas Silva, Jose Luis
A1 Barbosa, Nuno
A1 Encinas, Cristina
A1 Hernandez, Jose angel
A1 Alonso, Rafael
A1 Campos, Maria Luisa
A1 Rodriguez, Teresa
A1 Leivas, Alberto
A1 Olivares, Maria Jose
A1 Sanchez, Maria Jose
A1 Paiva, Bruno
A1 Lahuerta, Juan Jose
A1 Martinez-Lopez, Joaquin
K1 multiple myeloma (MM)
K1 heavy
K1 <p>heavy/light chain (HLC) assay</p>
K1 Hevylite(R)
K1 diagnosis
K1 prognosis
K1 monitoring
K1 International staging system
K1 Monoclonal gammopathy
K1 Undetermined significance
K1 Residual disease
K1 Uninvolved immunoglobulins
K1 Risk-factor
K1 Follow-up
K1 Long-term
K1 Progression
K1 Survival
AB Despite tremendous progress being made in recent years, multiple myeloma (MM) remains a challenging disease. The laboratory plays a critical role in the overall management of patients. The diagnosis, prognosis, clinical monitoring and evaluation of the response are key moments in the clinical care process. Conventional laboratory methods have been and continue to be the basis of laboratory testing in monoclonal gammopathies, along with the serum free light chain test. However, more accurate methods are needed to achieve new and more stringent clinical goals. The heavy/light chain assay is a relatively new test which can overcome some of the limitations of the conventional methods for the evaluation of intact immunoglobulin MM patients. Here, we report an update of the evidence accumulated in recent years on this method regarding its use in MM.
PB Mdpi
YR 2021
FD 2021-11-01
LK https://hdl.handle.net/10668/26468
UL https://hdl.handle.net/10668/26468
LA en
DS RISalud
RD Apr 8, 2025